Scientific Publications

mystile-demo

Peer-Reviewed Publications by Dr. Michael Har-Noy

For the official Immunovative Therapies, Ltd. corporate website, please visit www.immunovative.co.il

1)     Prolonged remission of advanced bronchoalveolar adenocarcinoma in a dog treated with utologous, tumour-derived chaperone-rich cell lysate (CRCL) vaccine.

Epple LM, Bemis LT, Cavanaugh RP, Skope A, Mayer-Sonnenfeld T, Frank C, Olver CS, Lencioni AM, Dusto NL, Tal A, Michael Har-Noy,* Lillehei KO, Katsanis E, Graner MW.

Int J Hyperthermia. 2013 Jun 20. [Epub ahead of print]

PMID:23786302[PubMed – as supplied by publisher

*Founder and CEO of Immunovative Therapies, Ltd.

2)     Proteomic analyses of different human tumour-derived chaperone-rich cell lysate (CRCL) anti-cancer vaccines reveal antigen content and strong similarities amongst the vaccines along with a basis for CRCL’s unique structure: CRCL vaccine proteome leads to unique structure.

Mayer-Sonnenfeld T, Michael Har-Noy,* Lillehei KO, Graner MW.

Int J Hyperthermia. 2013 Jun 4. [Epub ahead of print]

PMID:23734882[PubMed – as supplied by publisher]

*Founder and CEO of Immunovative Therapies, Ltd.

 

3)     Th-1 lymphocytes induce dendritic cell tumor killing activity by an IFN-γ-dependent mechanism.

LaCasse CJ, Janikashvili N, Larmonier CB, Alizadeh D, Hanke N, Kartchner J, Situ E, Centuori S, Michael Har-Noy,* Bonnotte B, Katsanis E, Larmonier N.

J Immunol. 2011 Dec 15;187(12):6310-7. doi: 10.4049/jimmunol.1101812. Epub 2011 Nov 9.

PMID:22075702[PubMed – indexed for MEDLINE]

*Founder and CEO of Immunovative Therapies, Ltd.

 

4)     Allogeneic effector/memory Th-1 cells impair FoxP3+ regulatory T lymphocytes and synergize with chaperone-rich cell lysate vaccine to treat leukemia.

Janikashvili N, LaCasse CJ, Larmonier C, Trad M, Herrell A, Bustamante S, Bonnotte B, Michael Har-Noy,*  Larmonier N, Katsanis E.

Blood. 2011 Feb 3;117(5):1555-64. doi: 10.1182/blood-2010-06-288621. Epub 2010 Dec 1.

PMID:21123824[PubMed – indexed for MEDLINE]

*Founder and CEO of Immunovative Therapies, Ltd.

 

5)     Allogeneic CD3/CD28 cross-linked Th1 memory cells provide potent adjuvant effects for active immunotherapy of leukemia/lymphoma.

Michael Har-Noy,*  Zeira M, Weiss L, Fingerut E, Or R, Slavin S.

Leuk Res. 2009 Apr;33(4):525-38. doi: 10.1016/j.leukres.2008.08.017. Epub 2008 Oct 1.

PMID:18834631[PubMed – indexed for MEDLINE]

*Founder and CEO of Immunovative Therapies, Ltd.

 

 

6)     Completely mismatched allogeneic CD3/CD28 cross-linked Th1 memory cells elicit anti-leukemia effects in unconditioned hosts without GVHD toxicity.

Michael Har-Noy,* Zeira M, Weiss L, Slavin S.

Leuk Res. 2008 Dec;32(12):1903-13. doi: 10.1016/j.leukres.2008.05.007. Epub 2008 Jun 18.

PMID:18565579[PubMed – indexed for MEDLINE]

*Founder and CEO of Immunovative Therapies, Ltd.

 

7)     The anti-tumor effect of allogeneic bone marrow/stem cell transplant without graft vs. host disease toxicity and without a matched donor requirement?

Michael Har-Noy,* Slavin S.

Med Hypotheses. 2008;70(6):1186-92. Epub 2007 Dec 3.

PMID:18054441[PubMed – indexed for MEDLINE]

*Founder and CEO of Immunovative Therapies, Ltd.

 

8)     Cannabidiol lowers incidence of diabetes in non-obese diabetic mice.

Weiss L, Zeira M, Reich S, Michael Har-Noy,* Mechoulam R, Slavin S, Gallily R.

Autoimmunity. 2006 Mar;39(2):143-51.

PMID:16698671[PubMed – indexed for MEDLINE]

*Founder and CEO of Immunovative Therapies, Ltd.

 

9)     The growth of cells with LAK activity in an automated tissue culture system (Acusyst P).

Alter BJ, Ochoa AC, Michael Har-Noy,* Keyport GM, Bach FH.

Prog Clin Biol Res. 1987;244:301-11. No abstract available.

PMID:3498955[PubMed – indexed for MEDLINE]

*Founder and CEO of Immunovative Therapies, Ltd.

 

10) Modulatory action of FSH on LH-induced follicular growth in rats.

Peluso JJ, Luttmer S, Michael Har-Noy.*

J Reprod Fertil. 1984 Sep;72(1):173-7.

PMID:6433010[PubMed – indexed for MEDLINE]

*Founder and CEO of Immunovative Therapies, Ltd.

 

11) Role of LH pulse amplitude in controlling rat ovarian oestradiol-17 beta secretion in vitro.

Peluso JJ, Downey MC, Michael Har-Noy.*

J Reprod Fertil. 1984 May;71(1):107-12.

PMID:6427453[PubMed – indexed for MEDLINE]

*Founder and CEO of Immunovative Therapies, Ltd.

 

12) Regulation of ovarian follicular growth and steroidogenesis by low-amplitude LH pulses.

Peluso JJ, Michael Har-Noy,* Steger RW.

Am J Physiol. 1984 Feb;246(2 Pt 2):R184-9.

PMID:6696143[PubMed – indexed for MEDLINE]

*Founder and CEO of Immunovative Therapies, Ltd.

 

13) The effect of an LH pulse on 3H-thymidine incorporation into cultured ovaries of metestrous rats.

Peluso JJ, Durkee T, Michael Har-Noy.*

Cell Tissue Res. 1984;238(1):159-63.

PMID:6435878[PubMed – indexed for MEDLINE]

*Founder and CEO of Immunovative Therapies, Ltd.

 

14) Follicular development, steroidogenesis and ovulation within ovaries exposed in vitro to hormone levels which mimic those of the rat estrous cycle.

Michael Har-Noy,* Steger RW, Peluso JJ.

Biol Reprod. 1983 Dec;29(5):1265-75.

PMID:6418225[PubMed – indexed for MEDLINE]

*Founder and CEO of Immunovative Therapies, Ltd.

 

15) Capacity of fertilized ova from mature and middle-aged rats to undergo preimplantation development in vitro.

Peluso JJ, Karey K, Michael Har-Noy.*

Cell Tissue Res. 1983;229(2):451-6.

PMID:6850756[PubMed – indexed for MEDLINE]

*Founder and CEO of Immunovative Therapies, Ltd.